Neurology® Podcast

Genetic causes of ataxia

1) Evidence-based guideline on periprocedural management of antithrombotic medications and neurovascular disease and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Melissa Armstrong about the guideline on periprocedural management of antithrombotic medications and neurovascular disease. Dr. Roy Strowd is reading our e-Pearl of the week about HINTS of stroke. In the next part of the podcast Dr. Binit Shah interviews Dr. Kapil Sethi about management of of non-dopa responsive axial motor symptoms. The participants had nothing to disclose except Drs. Armstrong, Strowd and Sethi.Dr. Armstrong serves on Neurology, Level of Evidence Review Team; received funding for a trip to the MDS International Congress; received research support from Abbott and was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Sethi serves on the scientific advisory board for International Essential Tremor Foundation; serves as an editorial board member of Neurology, Journal of Neuroscience, Medscape; is a consultant for Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; serves on the speakers' bureau of Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; received publishing royalties from Marcel Dekker Publisher; holds stock options in Elan Corporation and Pfizer Inc; involved in legal proceedings for welding litigation defense; receives research support from NPF center, Biogen Idec, GlaxoSmithKline, Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Acadia Pharmaceuticals, Inc. and NIH.

1) Growing burden of neurodegenerative conditions and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Ray Dorsey about his paper on obtaining care for the growing burden of neurodegenerative conditions. Dr. Roy Strowd is reading our e-Pearl of the week about Huntington disease and the milk maid grip. In the next part of the podcast Dr. Binit Shah interviews Dr. Michael Okun about surgical management of Parkinson disease. The participants had nothing to disclose except Drs. Dorsey and Strowd.Dr. Dorsey serves on the scientific advisory board for Lundbeck Inc. and Huntington's Disease Society of America; serves as an editorial board member of Journal of Huntington's Disease; is a consultant for Avid Radiopharmaceuticals, Inc., Clintrex, Lundbeck, Inc., Medtronic, Inc., National Institute of Neurological Disorders and Stroke; (30% effort) clinical practice as a movement disorder neurologist; receives research support from Google, Lundbeck, Inc.; Prana Biotechnology Limited, National Institute of Neurological Disorders and Stroke, Agency for Health Care Research and Quality; Macklin Foundation, Inc, and Verizon Foundation; holds stock options in ConsultingMD and a patent application related to telemedicine.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) MRI sign of progressive supranuclear palsy and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Luke Massey about his paper on an MRI sign of progressive supranuclear palsy. Dr. Roy Strowd is reading our e-Pearl of the week about the hummingbird sign. In the next part of the podcast Dr. Matthew Barrett interviews Dr. Fred Wooten about late treatment of motor symptoms. The participants had nothing to disclose except Drs. Morgan, Massey and Strowd.Dr. Morgan is a consultant for Impax Laboratories, Inc. and Veloxis Pharmaceuticals; serves on the speakers' bureaus of GlaxoSmithKline, Teva Pharmaceuticals Industries Ltd., UCB and GE Healthcare; performed CME for Oakstone Publishing, LLC; receives research support from the NIH and received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic conditions.Dr. Massey received research support from the PSP Association Europe.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Diagnosis of gluten ataxia and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Marios Hadjivassiliou about his paper on the diagnosis of gluten ataxia. Dr. Roy Strowd is reading our e-Pearl of the week about tonic spasms in multiple sclerosis. In the next part of the podcast Dr. Matthew Barrett interviews Dr. Fred Wooten about early treatment of motor symptoms. The participants had nothing to disclose except Dr. Strowd.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

Immune mediated, toxic & infectious ataxias

1) Exposure to stroke belt on incident stroke and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Virginia Howard about her paper on exposure to the stroke belt on incident stroke in adulthood. Dr. Adam Numis is reading our e-Pearl of the week about Neuro-Behcet's disease. In the next part of the podcast Dr. Brett Kissela focuses his interview with Dr. Chelsea Kidwell about the MR Rescue trial. The participants had nothing to disclose except Drs Howard, Numis, Kissela and Kidwell.Dr. Howard serves on DSMB for NIH-NIDA; is a consultant for NIH review committees and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Kidwell serves as an editorial board member of Stroke, Neurocritical Care Journal, Journal of Neuroimaging and Stroke Research and Treatment; and receives research support from Baxter and NIH.

1) Atrial fibrillation and unexplained stroke and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Paul Cotter about his paper on incidence of atrial fibrillation and unexplained stroke. Dr. Adam Numis is reading our e-Pearl of the week about LGI-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Brett Kissela interviews Drs. Opeolu Adeoye and Art Pancioli about the CLEAR-ER trial. The participants had nothing to disclose except Drs Cotter, Numis, Kissela and Adeoye.Dr. Cotter receives research support from the UK National Institute for Health Research, Cambridge biomedical Research Center and Clinical Research Fellowship.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Adeoye received honoraria for serving on the speakers' bureau of Genentech, Inc. and receives research support from the NIH.

1) Human herpes 6 virus encephalitis and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Mina Bhanushali and Sarah Kranick about their paper on human herpes 6 virus encephalitis and stem cell transplantation. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Brett Kissela interviews Dr. Clay Johnston about CHANCE trial. All the participants have disclosures.Dr. Jen serves as an Associate Editor of Frontiers in Neuro-otology and Section Editor of Experimental Brain Research and receives research support from the FDA.Ms. Kranick is a staff member of the National Institute of Health.Dr. Bhanushali Is an employee of the National Institute of Health.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Johnston serves as Co-Editor-in-Chief of Journal Watch Neurology; serves as Vice Editor of Annals of Neurology; is co-holder of patent on the RNA panel to identify TIA and risk stratify; Stryker Neurovascular, Boston Scientific, Kaiser-Permanente, NCRR/NCATS, CTSA, AHA/ASA, Bugher Award and the NIH and provided expert testimony in legal proceedings for GlaxoSmithKline.

1) PML diagnostic criteria: Consensus statement from AAN Neuroinfectious Disease Section and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Joseph Berger about the consensus paper from the PML Guidelines Committee of the AAN Neuroinfectious Disease Section. Dr. Andy Numis is reading our e-Pearl of the week about spinal epidural abscesses. In the next part of the podcast Dr. Brett Kissela interviews Dr. Marc Chimowitz about SAMMPRIS trial. The participants had nothing to disclose except Drs. Berger, Numis, Kissela and Chimowitz.Dr. Berger serves as an Associate Editor for the Journal of Neurovirology, serves as an editorial board member of ISRN Education, Neuroscience, World Journal of Rheumatology and MS and other related disorders; serves on the PML adjudication committees of Millenium/Takeda and Amgen; has served as a consultant to Millennium/Takeda, Amgen, Genzyme, Eisai and Novartis; and receives honoraria from Genzyme. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Chimowitz serves as an editorial board member for the journals Stroke and Neurosurgery; has received grant support from NIH/ NINDS to lead multicenter trials on the treatment of intracranial arterial stenosis; for these NIH funded trials, he has also received research support from Stryker Corporation (donation of intracranial stents, payments for 3rd party monitoring of trial), AstraZeneca Corporation (donation of statin), Bayer (donation of aspirin and placebo) and Bristol Myers Squibb (donation of warfarin and placebo); serves on the data safety monitoring board for an industry funded PFO closure study sponsored by Gore Corporation and on a stroke event adjudication panel for an osteoporosis trial funded by Merck and has also provided medico-legal reviews on stroke related cases.